"alt_sample_name"	"unique_patient_ID"	"sample_type"	"histological_type"	"primarysite"	"arrayedsite"	"summarygrade"	"summarystage"	"tumorstage"	"substage"	"grade"	"age_at_initial_pathologic_diagnosis"	"pltx"	"tax"	"neo"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"os_binary"	"relapse_binary"	"site_of_tumor_first_recurrence"	"primary_therapy_outcome_success"	"debulking"	"percent_normal_cells"	"percent_stromal_cells"	"percent_tumor_cells"	"batch"	"uncurated_author_metadata"
"GSM742565"	"US Patient 1"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	87	NA	NA	NA	NA	NA	1522	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 1///geo_accession: GSM742565///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 87///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1584///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17.5///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT1///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742566"	"US Patient 2"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	43	NA	NA	NA	NA	NA	2283	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 2///geo_accession: GSM742566///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 43///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 564///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 75///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT2///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742567"	"US Patient 3"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	61	NA	NA	NA	NA	NA	365	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 3///geo_accession: GSM742567///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 404///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 12///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT3///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742568"	"US Patient 4"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"b"	3	82	NA	NA	NA	NA	NA	30	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 4///geo_accession: GSM742568///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 12033///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 1///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT4///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742569"	"US Patient 5"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	57	NA	NA	NA	NA	NA	730	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 5///geo_accession: GSM742569///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1130///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/cpt11/tam/topo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT5///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742570"	"US Patient 6"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	3	"b"	1	40	NA	NA	NA	NA	NA	1400	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 6///geo_accession: GSM742570///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 40///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 523///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 46///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT6///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742571"	"US Patient 7"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	64	NA	NA	NA	NA	NA	426	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 7///geo_accession: GSM742571///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 64///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 128///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: SD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT7///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742572"	"US Patient 8"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	78	NA	NA	NA	NA	NA	670	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 8///geo_accession: GSM742572///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1831///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 22///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT8///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742573"	"US Patient 9"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	77	NA	NA	NA	NA	NA	852	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 9///geo_accession: GSM742573///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 77///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 424///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 28///characteristics_ch1.11: overall survival (os; months): 28///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT9///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742574"	"US Patient 10"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	69	NA	NA	NA	NA	NA	457	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 10///geo_accession: GSM742574///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 69///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 306///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT10///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742575"	"US Patient 11"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	52	NA	NA	NA	NA	NA	426	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 11///geo_accession: GSM742575///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 536///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/cc2103///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT11///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742576"	"US Patient 12"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	49	NA	NA	NA	NA	NA	2097	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 12///geo_accession: GSM742576///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 293///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: modifed triple doublets///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.8///characteristics_ch1.11: overall survival (os; months): 68.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT12///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742577"	"US Patient 13"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	82	NA	NA	NA	NA	NA	794	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 13///geo_accession: GSM742577///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 26.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT13///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742578"	"US Patient 14"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	52	NA	NA	NA	NA	NA	1972	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 14///geo_accession: GSM742578///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 793///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 64.8///characteristics_ch1.11: overall survival (os; months): 64.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT14///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742579"	"US Patient 15"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	NA	NA	724	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 15///geo_accession: GSM742579///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2792///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.2///characteristics_ch1.11: overall survival (os; months): 23.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT15///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742580"	"US Patient 16"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	63	NA	NA	NA	NA	NA	1053	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 16///geo_accession: GSM742580///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2983///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.6///characteristics_ch1.11: overall survival (os; months): 34.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT16///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742581"	"US Patient 17"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	48	NA	NA	NA	NA	NA	1004	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 17///geo_accession: GSM742581///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3723///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18.2///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT17///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742582"	"US Patient 18"	NA	"tumor"	"ser"	NA	NA	NA	"late"	3	"c"	NA	63	NA	NA	NA	NA	NA	1595	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 18///geo_accession: GSM742582///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Unknown///characteristics_ch1.5: preop. ca125: 3078///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 21.2///characteristics_ch1.11: overall survival (os; months): 52.4///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT18///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742583"	"US Patient 19"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	55	NA	NA	NA	NA	NA	192	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 19///geo_accession: GSM742583///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8942///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 2.7///characteristics_ch1.11: overall survival (os; months): 6.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT19///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742584"	"US Patient 20"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	66	NA	NA	NA	NA	NA	1144	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 20///geo_accession: GSM742584///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 9603///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.6///characteristics_ch1.11: overall survival (os; months): 37.6///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT20///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742585"	"US Patient 21"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	60	NA	NA	NA	NA	NA	1123	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 21///geo_accession: GSM742585///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 210///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxotere/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 2.6///characteristics_ch1.11: overall survival (os; months): 36.9///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT21///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742586"	"US Patient 22"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	60	NA	NA	NA	NA	NA	944	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 22///geo_accession: GSM742586///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP/IV platinum/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13.6///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT22///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742587"	"US Patient 23"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	60	NA	NA	NA	NA	NA	1428	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 23///geo_accession: GSM742587///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 20000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.9///characteristics_ch1.11: overall survival (os; months): 46.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT23///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742588"	"US Patient 24"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	62	NA	NA	NA	NA	NA	1470	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 24///geo_accession: GSM742588///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 696///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 48.3///characteristics_ch1.11: overall survival (os; months): 48.3///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT24///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742589"	"US Patient 25"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	84	NA	NA	NA	NA	NA	1007	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 25///geo_accession: GSM742589///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 84///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 33.1///characteristics_ch1.11: overall survival (os; months): 33.1///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT25///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742590"	"US Patient 26"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	73	NA	NA	NA	NA	NA	1440	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 26///geo_accession: GSM742590///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 789///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxane///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12///characteristics_ch1.11: overall survival (os; months): 47.3///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT26///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742591"	"US Patient 27"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	62	NA	NA	NA	NA	NA	950	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 27///geo_accession: GSM742591///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 802///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.5///characteristics_ch1.11: overall survival (os; months): 31.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT27///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742592"	"US Patient 28"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	4	NA	2	64	NA	NA	NA	NA	NA	1345	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 28///geo_accession: GSM742592///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 64///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 988///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 44.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT28///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742593"	"US Patient 29"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	51	NA	NA	NA	NA	NA	460	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 29///geo_accession: GSM742593///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1139///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 5.5///characteristics_ch1.11: overall survival (os; months): 15.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT29///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742594"	"US Patient 30"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	61	NA	NA	NA	NA	NA	1221	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 30///geo_accession: GSM742594///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 450///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: t/c, carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.2///characteristics_ch1.11: overall survival (os; months): 40.1///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT30///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742595"	"US Patient 31"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	74	NA	NA	NA	NA	NA	953	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 31///geo_accession: GSM742595///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2301///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12.2///characteristics_ch1.11: overall survival (os; months): 31.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT31///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742596"	"US Patient 32"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	72	NA	NA	NA	NA	NA	265	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 32///geo_accession: GSM742596///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1684///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 8.7///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT32///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742597"	"US Patient 33"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	67	NA	NA	NA	NA	NA	24	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 33///geo_accession: GSM742597///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2106///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 0.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT33///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742598"	"US Patient 34"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	3	"c"	2	66	NA	NA	NA	NA	NA	554	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 34///geo_accession: GSM742598///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 990///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.1///characteristics_ch1.11: overall survival (os; months): 18.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT34///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742599"	"US Patient 35"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	66	NA	NA	NA	NA	NA	846	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 35///geo_accession: GSM742599///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 281///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 27.8///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT35///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742600"	"US Patient 36"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	67	NA	NA	NA	NA	NA	1552	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 36///geo_accession: GSM742600///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 206///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 20.2///characteristics_ch1.11: overall survival (os; months): 51///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT36///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742601"	"US Patient 37"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	44	NA	NA	NA	NA	NA	749	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 37///geo_accession: GSM742601///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 44///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3738///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 10.4///characteristics_ch1.11: overall survival (os; months): 24.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT37///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742602"	"US Patient 38"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	76	NA	NA	NA	NA	NA	283	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 38///geo_accession: GSM742602///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2389///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: Unknown///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 9.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT38///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742603"	"US Patient 39"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	65	NA	NA	NA	NA	NA	995	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 39///geo_accession: GSM742603///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 65///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 104///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 32.7///characteristics_ch1.11: overall survival (os; months): 32.7///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT39///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742604"	"US Patient 40"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	56	NA	NA	NA	NA	NA	1644	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 40///geo_accession: GSM742604///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1591///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 54///characteristics_ch1.11: overall survival (os; months): 54///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT40///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742605"	"US Patient 41"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	71	NA	NA	NA	NA	NA	286	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 41///geo_accession: GSM742605///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1072///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 1.4///characteristics_ch1.11: overall survival (os; months): 9.4///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Feb-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT41///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742606"	"US Patient 42"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	61	NA	NA	NA	NA	NA	1254	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 42///geo_accession: GSM742606///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 146///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/Gemcitabine, carboplatin/taxol, adriamycin/topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19.8///characteristics_ch1.11: overall survival (os; months): 41.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT42///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742607"	"US Patient 43"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	59	NA	NA	NA	NA	NA	1613	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 43///geo_accession: GSM742607///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 26///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25.7///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT43///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742608"	"US Patient 44"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	56	NA	NA	NA	NA	NA	1114	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 44///geo_accession: GSM742608///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 534///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.1///characteristics_ch1.11: overall survival (os; months): 36.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT44///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742609"	"US Patient 45"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	58	NA	NA	NA	NA	NA	323	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 45///geo_accession: GSM742609///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 334///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.6///characteristics_ch1.11: overall survival (os; months): 10.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT45///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742610"	"US Patient 46"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	56	NA	NA	NA	NA	NA	557	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 46///geo_accession: GSM742610///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 600///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6.7///characteristics_ch1.11: overall survival (os; months): 18.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT46///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742611"	"US Patient 47"	NA	"tumor"	"ser"	NA	NA	NA	"late"	3	"c"	NA	55	NA	NA	NA	NA	NA	511	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 47///geo_accession: GSM742611///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Carcinoma arising in borderline///characteristics_ch1.5: preop. ca125: 619///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16.8///characteristics_ch1.11: overall survival (os; months): 16.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT47///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742612"	"US Patient 48"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	56	NA	NA	NA	NA	NA	426	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 48///geo_accession: GSM742612///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 229///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT48///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742613"	"US Patient 49"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	59	NA	NA	NA	NA	NA	1096	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 49///geo_accession: GSM742613///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3252///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (15X), tamoxifen, taxol (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT49///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742614"	"US Patient 50"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	78	NA	NA	NA	NA	NA	974	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 50///geo_accession: GSM742614///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 862.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X) then surgery and then taxol (6X), carboplatin (6x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT50///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742615"	"US Patient 51"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	76	NA	NA	NA	NA	NA	2739	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 51///geo_accession: GSM742615///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (6X),carbo (5x), topotecan (23x), gemcitabine (12x), tamoxifen, doxil (18x), xeloda (15x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 5///characteristics_ch1.11: overall survival (os; months): 90///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT51///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742616"	"US Patient 52"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	78	NA	NA	NA	NA	NA	30	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 52///geo_accession: GSM742616///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT52///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742617"	"US Patient 53"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	53	NA	NA	NA	NA	NA	517	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 53///geo_accession: GSM742617///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT53///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742618"	"US Patient 54"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	73	NA	NA	NA	NA	NA	1826	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 54///geo_accession: GSM742618///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11.7///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin (9x), taxol (12x), tamoxifen, XRt, xeloda (4x), doxil (9x), carboplatin (7x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT54///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742619"	"US Patient 55"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	78	NA	NA	NA	NA	NA	1157	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 55///geo_accession: GSM742619///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 338.3///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6x), carboplatin (4x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19///characteristics_ch1.11: overall survival (os; months): 38///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT55///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742620"	"US Patient 56"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	51	NA	NA	NA	NA	NA	4748	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 56///geo_accession: GSM742620///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 5140///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: cisplatin/taxol (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 151///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT56///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742621"	"US Patient 57"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	57	NA	NA	NA	NA	NA	670	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 57///geo_accession: GSM742621///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3398///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/cisplatin (7x), taxol/carboplatin (3x), carbo (6x), whole brain XRt, intra-thecal topotecan and iv topotecan (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 22///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT57///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742622"	"US Patient 58"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	77	NA	NA	NA	NA	NA	1126	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 58///geo_accession: GSM742622///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 77///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 548///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (3x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT58///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742623"	"US Patient 59"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	66	NA	NA	NA	NA	NA	2070	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 59///geo_accession: GSM742623///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 298///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X), subopt tRS, interferon (2x), carboplatin (12x), tamoxifen, doxorubicin (9x), taxol (3x), topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 68///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT59///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742624"	"US Patient 60"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	61	NA	NA	NA	NA	NA	4748	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 60///geo_accession: GSM742624///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (8X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 156///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jun-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT60///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742625"	"US Patient 61"	NA	"tumor"	"clearcell"	NA	NA	"high"	"late"	3	"c"	3	82	NA	NA	NA	NA	NA	730	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 61///geo_accession: GSM742625///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, endometrioid///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 981///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT61///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742626"	"US Patient 62"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	68	NA	NA	NA	NA	NA	1065	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 62///geo_accession: GSM742626///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 68///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2373.4///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 35///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT62///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742627"	"US Patient 63"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	56	NA	NA	NA	NA	NA	1826	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 63///geo_accession: GSM742627///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 382///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X),carboplatin(3X), doxil(12X), taxol/ avastin(5X), topotecan(3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT63///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742628"	"US Patient 64"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	59	NA	NA	NA	NA	NA	2009	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 64///geo_accession: GSM742628///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 144///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 66///characteristics_ch1.11: overall survival (os; months): 66///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT64///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742629"	"US Patient 65"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	67	NA	NA	NA	NA	NA	1918	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 65///geo_accession: GSM742629///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11713///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), caboplatin (11X), taxotere (6X), doxil (24X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 63///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT65///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742630"	"US Patient 66"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	72	NA	NA	NA	NA	NA	1248	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 66///geo_accession: GSM742630///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3705.6///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin/topotecan(4X), carbo/taxol(4X), doxil(4X), topotecan(2X), taxotere (3X), Xelado (3X), taxol (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT66///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742631"	"US Patient 67"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	71	NA	NA	NA	NA	NA	61	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 67///geo_accession: GSM742631///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2353///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT67///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742632"	"US Patient 68"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	74	NA	NA	NA	NA	NA	1948	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 68///geo_accession: GSM742632///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 715///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (2x), letrozole///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 28///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT68///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742633"	"US Patient 69"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	73	NA	NA	NA	NA	NA	1096	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 69///geo_accession: GSM742633///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 89.1///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), carboplatin (6x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT69///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742634"	"US Patient 70"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	49	NA	NA	NA	NA	NA	974	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 70///geo_accession: GSM742634///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3444.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (5X)/carboplatin (6X), taxol (9x), carboplatin (4x), doxil (4x), topotecan (3x), navelbine (2x), gemcitabine (2x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT70///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742635"	"US Patient 71"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	78	NA	NA	NA	NA	NA	1431	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 71///geo_accession: GSM742635///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 311///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), tamoxifen, femara///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT71///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742636"	"US Patient 72"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	45	NA	NA	NA	NA	NA	852	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 72///geo_accession: GSM742636///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (6X), carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 28///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT72///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742637"	"US Patient 73"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	59	NA	NA	NA	NA	NA	1126	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 73///geo_accession: GSM742637///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 156///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (8X), carboplatin (3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT73///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742638"	"US Patient 74"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	52	NA	NA	NA	NA	NA	1735	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 74///geo_accession: GSM742638///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 165///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin & doxil (6X), taxol/ carboplatin (6X), carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT74///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742639"	"US Patient 75"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	73	NA	NA	NA	NA	NA	1826	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 75///geo_accession: GSM742639///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 176///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: patient decided to have chemo elsewhere (standard treatment recommendation is carbo/taxol 6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 60///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT75///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742640"	"US Patient 76"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	45	NA	NA	NA	NA	NA	639	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 76///geo_accession: GSM742640///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2215///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ carboplatin (6X), topotecan (4X), carboplatin (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 21///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT76///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742641"	"US Patient 77"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	58	NA	NA	NA	NA	NA	1978	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: US Patient 77///geo_accession: GSM742641///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1693///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (9X), then taxol/carboplatin (one dose only due to severe neuropathy)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 49///characteristics_ch1.11: overall survival (os; months): 65///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT77///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742642"	"US Patient 78"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	60	NA	NA	NA	NA	NA	426	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 78///geo_accession: GSM742642///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 10.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT78///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742643"	"US Patient 79"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	60	NA	NA	NA	NA	NA	426	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 79///geo_accession: GSM742643///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1920///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT79///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742644"	"US Patient 80"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	"c"	3	47	NA	NA	NA	NA	NA	1918	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: US Patient 80///geo_accession: GSM742644///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 47///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 534.3///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: topotecan/carboplatin (4X), then taxol/carboplatin (4X), another carbo/taxol (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 63///characteristics_ch1.11: overall survival (os; months): 63///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT80///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742645"	"Norwegian patient 1"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	67	NA	NA	NA	NA	NA	152	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 1///geo_accession: GSM742645///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1100///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT1///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742646"	"Norwegian patient 2"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	61	NA	NA	NA	NA	NA	944	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 2///geo_accession: GSM742646///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 700///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT2///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742647"	"Norwegian patient 3"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	75	NA	NA	NA	NA	NA	2526	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 3///geo_accession: GSM742647///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 75///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1965///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 77///characteristics_ch1.11: overall survival (os; months): 83///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT3///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742648"	"Norwegian patient 4"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	52	NA	NA	NA	NA	NA	1948	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 4///geo_accession: GSM742648///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 761///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: 2002 jan///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT4///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742649"	"Norwegian patient 5"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	51	NA	NA	NA	NA	NA	1035	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 5///geo_accession: GSM742649///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 24290///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 4///characteristics_ch1.11: overall survival (os; months): 34///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT5///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742650"	"Norwegian patient 6"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	4	NA	2	66	NA	NA	NA	NA	NA	1613	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 6///geo_accession: GSM742650///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1331///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT6///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742651"	"Norwegian patient 7"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	60	NA	NA	NA	NA	NA	822	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 7///geo_accession: GSM742651///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 375///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 27///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT7///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742652"	"Norwegian patient 8"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	48	NA	NA	NA	NA	NA	304	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 8///geo_accession: GSM742652///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 40790///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 10///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT8///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742653"	"Norwegian patient 9"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	74	NA	NA	NA	NA	NA	2192	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 9///geo_accession: GSM742653///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1395///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 65///characteristics_ch1.11: overall survival (os; months): 72///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT9///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742654"	"Norwegian patient 10"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	60	NA	NA	NA	NA	NA	791	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 10///geo_accession: GSM742654///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1903///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6///characteristics_ch1.11: overall survival (os; months): 26///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT10///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742655"	"Norwegian patient 11"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	3	NA	1	30	NA	NA	NA	NA	NA	1735	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 11///geo_accession: GSM742655///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 30///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 933///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT11///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742656"	"Norwegian patient 12"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	3	NA	1	42	NA	NA	NA	NA	NA	1704	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 12///geo_accession: GSM742656///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 42///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 99///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 56///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT12///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742657"	"Norwegian patient 13"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	3	NA	1	58	NA	NA	NA	NA	NA	1522	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 13///geo_accession: GSM742657///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 241///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT13///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742658"	"Norwegian patient 14"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	4	NA	2	59	NA	NA	NA	NA	NA	1583	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 14///geo_accession: GSM742658///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 2966///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 52///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT14///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742659"	"Norwegian patient 15"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	50	NA	NA	NA	NA	NA	1431	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 15///geo_accession: GSM742659///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 637///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 36///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT15///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742660"	"Norwegian patient 16"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	50	NA	NA	NA	NA	NA	1431	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 16///geo_accession: GSM742660///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 492///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT16///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742661"	"Norwegian patient 17"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	79	NA	NA	NA	NA	NA	152	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 17///geo_accession: GSM742661///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 79///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 230///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT17///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742662"	"Norwegian patient 18"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	53	NA	NA	NA	NA	NA	1004	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 18///geo_accession: GSM742662///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1354///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT18///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742663"	"Norwegian patient 19"	NA	"tumor"	"ser"	NA	NA	"low"	"late"	4	NA	2	62	NA	NA	NA	NA	NA	1248	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 19///geo_accession: GSM742663///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1145///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jum-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT19///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742664"	"Norwegian patient 20"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	56	NA	NA	NA	NA	NA	883	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 20///geo_accession: GSM742664///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 305///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 29///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT20///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742665"	"Norwegian patient 21"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	71	NA	NA	NA	NA	NA	457	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 21///geo_accession: GSM742665///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 937///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT21///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742666"	"Norwegian patient 22"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	3	NA	3	56	NA	NA	NA	NA	NA	1096	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Norwegian patient 22///geo_accession: GSM742666///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2359///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 31///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT22///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
"GSM742667"	"Norwegian patient 23"	NA	"tumor"	"ser"	NA	NA	"high"	"late"	4	NA	3	76	NA	NA	NA	NA	NA	517	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Norwegian patient 23///geo_accession: GSM742667///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1400///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-1999///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT23///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380"
